Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis

Inclusion Criteria: * Age 6 - \< 18 years * Diagnosis of SHPT with the mean of the two consecutive central laboratory iPTH values ≥ 300 pg/mL during screening * Corrected calcium value of ≥ 8.8 mg/dL during screening * Diagnosis of CKD, receiving either hemodialysis or peritoneal dialysis, for ≥ 30 days prior to screening * Parent or legally acceptable representative has provided written informed consent and subject has provided written assent when required by institutional guidelines Exclusion Criteria: * History of congenital long QT syndrome, second or third degree heart block, ventricular tachyarrhythmias or other conditions associated with prolonged QT interval * Corrected QT interval (QTc) \> 500 ms, using Bazett's formula * QTc ≥ 450 to ≤ 500 ms, using Bazett's formula, unless written permission to enroll is provided by the investigator after consultation with a pediatric cardiologist * Use of grapefruit juice, herbal medications, or potent cytochrome P450 3A4 (CYP3A4) inhibitors (eg, erythromycin, clarithromycin, ketoconazole, itraconazole) * Use of concomitant medications that may prolong the QTc interval (eg, ondansetron, albuterol)